Rituximab/BEAM versus 131 Iodine-Tositumomab/BEAM prior to SCT for Relapsed DLBCL


Rituximab/BEAM versus 131 Iodine-Tositumomab/BEAM prior to SCT for Relapsed DLBCL
Slides from a presentation at ASH 2011 and transcribed comments from recent interviews with Owen A O’Connor, MD, PhD (2/3/12) and Craig Moskowitz, MD (1/11/12)

Vose JM et al. Randomized Phase III trial of 131iodine-tositumomab/carmustine, etoposide, cytarabine, melphalan (BEAM) vs rituximab/BEAM and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): No difference in progression-free (PFS) or overall survival (OS). Proc ASH 2011;Abstract 661.

Dr O'Connor is Professor of Medicine and Developmental Therapeutics and Director of the Center for Lymphoid Malignancies at Columbia University Medical Center in New York, New York.

Dr Moskowitz is Clinical Director in the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Medical College of Cornell University in New York, New York.